α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases
Brzoska T, Luger TA, Maaser C, Abels C, Böhm M
Endocrine Reviews (2008)
The canonical *Endocrine Reviews* synthesis of alpha-MSH and its C-terminal tripeptide KPV across fever, dermatitis, vasculitis, arthritis, colitis, uveitis, and brain inflammation — the field's high-water-mark review of the pharmacophore-dissection argument for KPV as a non-pigmenting anti-inflammatory.
This 2008 Endocrine Reviews paper from the Brzoska–Luger group in Münster is the canonical synthesis of alpha-melanocyte-stimulating hormone biology relevant to inflammatory disease and the most cited single review supporting interest in KPV. The authors trace alpha-MSH from its proopiomelanocortin precursor through the melanocortin-receptor family (MC1R–MC5R), characterise the cell types that produce and respond to it (keratinocytes, melanocytes, monocytes, macrophages, dendritic cells, T cells, intestinal epithelium), and document the molecular pathways alpha-MSH modulates: NF-κB activation, chemokine-receptor expression, IL-10 induction, pro-inflammatory cytokine suppression, T-cell proliferation, and inflammatory-cell migration. They then synthesise the animal-model evidence across fever, contact dermatitis, vasculitis, fibrosis, ocular inflammation, gastrointestinal inflammation, brain inflammation, allergic airway inflammation, and arthritis — concluding that alpha-MSH has reproducible protective effects across nearly every major inflammation paradigm. The review's most consequential argument is the pharmacophore-dissection case for KPV: by isolating the C-terminal tripeptide, the anti-inflammatory activity can be preserved while the pigmentary activity — which would otherwise rule out alpha-MSH as a chronic-therapeutic — is eliminated. This argument has driven essentially every subsequent KPV-development paper.
This is a narrative review, not a systematic review or meta-analysis. The breadth of conditions covered comes with the inherent compromise that no single therapeutic claim is examined at the depth a focused meta-analysis would require. The KPV pharmacophore-dissection argument is mechanistically clean but at the time of writing relied principally on rodent and in-vitro evidence — the eighteen years since publication have produced nanoparticle-delivery work and small case reports but not a large randomized human trial that would close the translational gap the review hoped to motivate. The melanocortin-receptor literature has continued to evolve since 2008: the relative contributions of MC1R, MC3R, and MC5R to peripheral anti-inflammatory actions are now understood with more nuance than the review captures, and the MC1Re/e mouse-colitis data published alongside this review (Kannengiesser 2008) made the MC1R-independence of KPV's activity sharper than the review's mechanistic framing.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.